Shanghai Shunho: No Research on Oral Tobacco Products Undertaken Yet

Nov.29.2024
Shanghai Shunho: No Research on Oral Tobacco Products Undertaken Yet
Shanghai Shunho New Materials Technology announced that the company has not yet conducted any research related to oral tobacco products.

Recently, investors on the Investor Interaction Platform inquired Shanghai Shunho New Materials Technology  (002565.SZ) about the progress of the company and its subsidiaries or affiliated companies in the research and development of oral tobacco (nicotine pouch) products, as well as whether there are any related patent reserves.

 

In response, Shunho Corporation stated that the company has not yet conducted any research related to smokeless tobacco products and expressed gratitude for the investors' attention.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

British Columbia Sues Juul Over Youth Nicotine Addiction
British Columbia Sues Juul Over Youth Nicotine Addiction
British Columbia has filed a civil lawsuit against Juul Labs, alleging the company fuelled youth nicotine addiction through highly addictive products and deceptive marketing practices. The claim was submitted to the B.C. Supreme Court under the newly enacted Vaping Product Damages and Health Care Costs Recovery Act.
Dec.15 by 2FIRSTS.ai
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.
Dec.22 by 2FIRSTS.ai
Azerbaijan’s Milli Majlis passes final reading bill banning e-cigarettes and their components
Azerbaijan’s Milli Majlis passes final reading bill banning e-cigarettes and their components
Azerbaijan’s Milli Majlis adopted in final reading a bill banning the import, export, production, storage, wholesale and retail sale, and use of electronic cigarettes and their components, through amendments to the law On Tobacco and Tobacco Products. The document states that nicotine-containing electronic cigarettes are included within the concept of tobacco products and sets out a definition of electronic cigarettes.
Dec.31 by 2FIRSTS.ai
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
At the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, PMI CEO Jacek Olczak delivered a clear message: the company’s smoke-free shift is now its central strategy. From ZYN’s surge in the U.S. to IQOS’s global momentum and a changing regulatory tone, his remarks sounded less like an earnings update and more like a declaration of PMI’s smoke-free future.
PMI
Dec.03
Washington Policy Media Flags Surge: China’s Monthly Vape Exports Jump from 2.2M Kg to 14.8M Kg; Crackdown Effectiveness Questioned
Washington Policy Media Flags Surge: China’s Monthly Vape Exports Jump from 2.2M Kg to 14.8M Kg; Crackdown Effectiveness Questioned
The Washington Examiner on December 9, 2025, reported: China's vape export volume to the U.S. rebounded sharply from 2.2 million kilograms to 14.8 million kilograms despite the crackdown. This volatility, confirming the annual multi-billion dollar trade gap, is the "Bullwhip Effect" in action. It transfers massive inventory to the U.S. market, putting the working capital of Chinese manufacturers and the supply chain at severe risk of lock-up and failure. Regulatory escalation is now imminent.
News
Dec.11